4-oxoimidazolidine-2-spiropiperidine derivatives

Details 4-oxoimidazolidine-2-spiropiperidine derivatives 4-oxoimidazolidine-2-spiropiperidine derivatives

2007-03-20

2007-03-20

Desai, Rita (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S020000

Reexamination Certificate

active

10484765

ABSTRACT:
The invention relates to 4-oxoimidazolidine-2-spiropiperidine derivatives represented by a general formula [I][in which A1, A2, A3, A4and A5stand for optionally halogen-substituted methine, or nitrogen atom; R1and R2stand for lower alkyl or the like; R3stands for hydrogen or lower alkyl; R4and R5stand for hydrogen, or lower alkyl which is optionally substituted with hydroxy, or the like]or salts thereof. These compounds act as nociceptin receptor agonist, and are useful as analgesic, reliever from tolerance to narcotic analgesic, reliever from dependence on narcotic analgesic, analgesic enhancer, antiobestic, drug for ameliorating brain function, remedy for schizophrenia, drug for treating regressive neurodegenerative diseases, antianxiety agent or antidepressant and remedy for diabetes insipidus and polyuria; and the like.

REFERENCES:
patent: 6043366 (2000-03-01), Adam et al.
patent: 997464 (1999-10-01), None
patent: 1-207291 (1989-08-01), None
patent: 2000-169476 (2000-06-01), None
patent: 00/34280 (2000-06-01), None
patent: 01/96337 (2001-12-01), None
Francois Jenck et al., “Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress”, Proceedings of the National Academy of Sciences of the United States, 94, pp. 14854-14858, 1997.
Anna Rizzi et al., “Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice” Naunyn-Schmiedeberg's Archives of Pharmacology, 363, pp. 161-165, 2001.
Francois Jenck et al., “A synthetic agonist at the orphanin FQ
ociceptin receptor ORL1: Anxiolytic profile in the rat”, Proceedings of the National Academy of Sciences of the United States of America, 97, pp. 4938-4943, 2000.
Charles N. Allen et al., “Orphanin-FQ/Nociceptin (OFQ/N) Modulates the Activity of Suprachiasmatic Nucleus Neurons”, Journal of Neuroscience, 19, pp. 2152-2160, 1999.
Graeme Henderson et al., “The orphan opioid receptor and its endogenous ligand-nociceptin/orphanin FQ”, TiPS, 18, pp. 293-300, 1997.
David Julius, “Home for an orphan endorphin”, Nature, 377, p. 476, 1995.
Axel Fischer et al., “Nociceptin-Induced Inhibition of Tachykinergic Neurotransmission in Guinea Pig Bronchus”, Journal of Pharmacology & Experimental Therapeutics, 285, pp. 902-907, 1998.
Hunter C. Champion et al., “Nociceptin, a novel endogenous ligand for the ORL1receptor, has potent erectile activity in the cat”, American Journal of Physiology, 273, pp. E214-E219, 1997.
Zbigniew K. Krowicki et al., “Orphanin FQ
ociceptin and [Phe1φ(CH2-NH)Gly2]nociceptin(1-13)-NH2stimulate gastric motor function in anaesthetized rats”, British Journal of Pharmacology, 130, pp. 1639-1645, 2000.

Affiliated with

Also associated with

Rating

4-oxoimidazolidine-2-spiropiperidine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 4-oxoimidazolidine-2-spiropiperidine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-oxoimidazolidine-2-spiropiperidine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3773340